Ignite Creation Date:
2024-05-05 @ 9:31 PM
Last Modification Date:
2024-10-26 @ 10:05 AM
Study NCT ID:
NCT00902174
Status:
COMPLETED
Last Update Posted:
2016-02-17
First Post:
2009-05-13
Brief Title:
Imatinib QTI571 in Pulmonary Arterial Hypertension
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A 24-week Randomized Placebo-controlled Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension Imatinib in Pulmonary Arterial Hypertension a Randomized Efficacy Study IMPRES
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMPRES
Brief Summary:
A multinational multicenter double blind placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension PAH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None